FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab

The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news